Health budget implications of mechanical thrombectomy for acute ischaemic stroke in Australia.

Introduction: This research evaluates the budget impact of treating acute ischaemic stroke (AIS) using a combination of mechanical thrombectomy (MT) with stent retrievers (SR) and intravenous tissue-plasminogen activator (IV-tPA) in Australia.

Methods: This study examined the economic impact over five years for a patient cohort based on the number of patients treated with MT+ IV-tPA in Australia 2021, versus treatment with IV-tPA alone. A budget impact (BI) model was developed to project direct medical costs (economic impact) of IV-tPA+ MT with SR vs.

Editorial: Medical Education in Difficult Circumstances.

This article was migrated. The article was marked as recommended. Not indicated.

Clinical properties of a novel, glistening-free, single-piece, hydrophobic acrylic IOL.

A new, single-piece, hydrophobic acrylic lens - the first constructed with a lens optic and haptics comprised of a hydroxyethyl methacrylate-polyethylene glycol phenyl ether acrylate-styrene copolymer, cross-linked with ethylene glycol dimethacrylate, and labeled as "glistening-free" - was recently introduced globally. Glistenings have been a significant source of clinical concern with previous hydrophobic lens designs. This new monofocal lens provides enhanced, clear optics for lens-based surgery.

Phase Ib single- and multiple-dose pharmacokinetic study of oral NV-52 in healthy volunteers.

Background And Objective: NV-52 is a novel synthetic flavonoid thromboxane synthase (TXS) inhibitor that may be useful for the maintenance of remission in inflammatory bowel disease (IBD). This study was conducted to determine the single- and multiple-dose pharmacokinetics of NV-52 in nine healthy volunteers (five men, four women; mean [+/- SD] age 23 +/- 2 years).

Methods: NV-52 400 mg was administered once daily for 10 days (excluding day 2) in an open-label study.

Serine proteases, their inhibitors and allergy.

This paper reviews four serine protease inhibitors and three protease gene defects that are associated with allergic conditions, suggesting an important role for these genes and their products in the development of allergy. Serine protease inhibitors may have a therapeutic potential in the treatment of allergy.